GAUDIUMIVF · NSE
Gaudium IVF and Women Health Limited
₹116.22
+1.25% (+₹1.43)
Prev. close
₹114.79
Volume
1,55,323
Delivery %
68.6%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Gaudium IVF and Women Health Limited
Gaudium IVF and Women Health Limited provides in vitro fertilization (IVF) treatment in India. The company offers fertility and reproductive health services, including intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), and ovulation induction; polycystic ovarian syndrome (PCOS)/ polycystic ovarian disease (PCOD); endometriosis treatment; ovulation induction; and laser assisted embryo implantation services. It also provides male infertility treatment services; egg freezing; embryo freezing; frozen embryo transfer; gynae consultation; laparoscopy for infertility; diagnostic services; and support and counselling services. In addition, the company operates hospital, in-house pharmacy; and 7 hubs (IVF centers) and 28 spokes. The company was founded in 2009 and is based in New Delhi, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Dr. Manika Khanna
Headquarters
New Delhi
Employees
120
Website
gaudiumivfcentre.comExchange
View on NSE ↗Key stats
Market cap
₹845.93 Cr
P/E ratio (TTM)
36.4
EPS (TTM)
₹3.19
Shares float
2.04 Cr
EPS · quarter ended Jun 2026
₹0.25
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹44.24 Cr | ₹47.89 Cr | ₹70.72 Cr | ₹104.36 Cr | |
| EBITDA | ₹20.09 Cr | ₹19.54 Cr | ₹28.87 Cr | ₹38.24 Cr |
| ₹13.53 Cr | ₹10.32 Cr | ₹19.17 Cr | ₹24.46 Cr | |
| Diluted EPS | ₹1.86 | ₹1.42 | ₹2.4 | ₹3.92 |
Total expenses (as filed), Employee benefit expense, Other expenses have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹36.63 Cr | ₹51.01 Cr | ₹88.51 Cr | ₹193.10 Cr | |
| ₹11.55 Cr | ₹17.40 Cr | ₹20.61 Cr | ₹24.57 Cr | |
| Stockholders' equity | ₹22.73 Cr | ₹26.99 Cr | ₹46.30 Cr | ₹152.30 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹23.85 Cr | ₹3.44 Cr | ₹8.72 Cr | ₹7.25 Cr | |
| Investing cash flow | ₹-15.63 Cr | ₹-5.40 Cr | ₹-15.17 Cr | ₹-87.65 Cr |
| ₹5.25 Cr | ₹-1.24 Cr | ₹1.82 Cr | ₹81.98 Cr | |
| Capital expenditure | ₹-15.26 Cr | ₹-2.79 Cr | ₹-8.88 Cr | ₹-6.72 Cr |
| End cash position | ₹15.06 Cr | ₹11.86 Cr | ₹7.22 Cr | ₹8.79 Cr |
Debt repaid, Dividends paid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Gaudium IVF and Women Health Limited | ₹835.52 Cr | ₹116.22 | 36.0 | 5.49 | 16.1% | 0.16 | +47.6% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is a free-float market-cap-share estimate from NSE’s live index data, not NSE’s own published (and sometimes capped) index weight. Indices without a live weight feed are listed without one, in alphabetical order after the weighted ones.
Indias First Listed IVF Company, Gaudium IVF, Unveils AI Powered Signature Labs, Kicking Off Planned 19 Centre Expansion
TheWire.in · 2 months ago